Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Phase 2

Terminated

Brief Summary: The purpose of this study is to evaluate the effects (good and bad) of the combination of ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade) in patients with relapsed/refractory mantle cell lymphoma.

Zevalin is a monoclonal antibody that is combined with a radioactive substance and given with another monoclonal antibody called rituximab (Rituxan). It works by attaching to cancer cells and releasing radiation to damage those cells. Both Zevalin and Rituxan are given in this study, along with Velcade.

Detailed Description: This is a non-randomized, unblinded single arm Phase II trial to evaluate the combination of yttrium90 ibritumomab tiuxetan and bortezomib in patients with relapsed/refractory mantle cell lymphoma (MCL). Standard hematology and chemistries, imaging and bone marrow biopsies will be done.

Research tests: 17cc of blood will be collected at screen, Day 8 OR 11 and month 3. Samples will be collected and stored for future analysis. These analyses may include but are not limited to measurements of proteasome inhibition. No genetic studies will be performed on these samples. Samples will be destroyed at the end of the study.

Primary Objective Estimate the overall response rate (CR + PR) of the combination of bortezomib and ibritumomab tiuxetan in patients with relapsed/refractory mantle cell lymphoma.

Secondary Objectives

* Estimate the progression free and overall survival in patients with relapsed/refractory mantle cell lymphoma who receive bortezomib and ibritumomab tiuxetan.

* Assess the toxicity of the combination of bortezomib and ibritumomab tiuxetan in patients with relapsed/refractory MCL.

Recruitment & Eligibility

Inclusion Criteria

Patients with relapsed or refractory Mantle Cell lymphoma with measurable disease.
Age > 18 years old
Expected survival >/= 3 months
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 at initiation of study (Appendix I).
Laboratory tests meet the levels specified in the protocol

Exclusion Criteria

Patients must not have received chemotherapy, radiation or surgical resection of malignancy within 3 weeks of study initiation. However, if they have received nitrosurea or mitomycin C then they should not be enrolled in the study until 6 weeks after therapy was last received.
No limitations to number of prior therapies
No prior radioimmunotherapy (RIT)
Prior bortezomib is allowed
Patient must be fully recovered from all toxicities associated with prior surgery, radiation treatment, chemotherapy or immunotherapy.
No active, serious infection or medical or psychiatric illness likely to interfere with participation in this clinic trial
No known HIV infection
No active central nervous system (CNS) involvement
Bone Marrow Involvement >/= 25% within 30 days of initiation of study treatment
Pregnant or breast feeding
No patients who have received Granulocyte colony-stimulating factor (G-CSF) or Granulocyte macrophage colony-stimulating factor (GM-CSF) within the 14 days prior to initiating protocol
No patient who has had major surgery within the four weeks prior to initiating protocol therapy
No patients with pleural effusion or significant ascites

Arm && Interventions

Group	Intervention	Description
Zevalin + Velcade	Rituximab, Bortezomib,Y90 ibritumomab tiuxetan	Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan Other Names: Rituxan Velcade Zevalin Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4 millicurie (mCi)/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.

Primary Outcome Measures

Name	Time	Method
Response Rate (Complete Response + Partial Response)	3 months	Disease will be assessed every 3 months. The Cheson criteria will be used to define response: Complete Response = Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present prior to therapy. Partial Response = A decrease of ≥ 50% in the sum of the products of their greatest transverse diameters (SPD) of up to six of the largest dominant nodes or nodal masses. These nodes or masses should be selected according to the following features: a) they should be clearly measurable in at least two perpendicular measurements; b) they should be from as disparate regions of the body as possible; and c) they should include mediastinal and retroperitoneal areas of disease whenever these sites are involved.

Secondary Outcome Measures

Name	Time	Method
Overall Survival at 1 Year	1 year	Number of participants who were alive at the 1 year time point. (Overall survival will be defined as the time from on-study to death due to any cause.)
Number of Participants With Progression Free Survival	6 months	Progression-free survival will be defined as time from on-study to disease progression or death, whichever comes first
Overall Survival at 5 Year	5 year	Number of participants who were alive at the 5 year time point. (Overall survival will be defined as the time from on-study to death due to any cause.)

Locations (1): Duke University Medical Center
🇺🇸
Durham, North Carolina, United States